

VBC Release Highlights

November 17, 2023

Practice InsightsSM is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

MIPS Quality Measures Dashboard

Launching new MIPS #462 measure

Starting Monday, Nov. 20, 2023, MIPS #462: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy will be available on the MIPS Quality Measures Dashboard.

This is a new measure offering for 2023 and intended to use this first year as a baseline to establish best practices for Bone Density documentation. In addition to an E/M visit within the reporting period, a Prostate cancer diagnosis must be documented in the problem list along with documentation of a Bone Density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment.

The key call-out is that only bone density scans documented within the Prostate Cancer problem will meet the measure. The teams will consider some document types for next year to include in the numerator met, but 2023 will focus on the Prostate Problem documentation. Practices will notice low numerators as we work together to establish best practices for Bone Density documentation.

Latest technical refinements to existing measures

The dashboard has been updated to reflect the below refinement(s) for:

NOTE: Table continues on the next page.

Measure	Description	
MIPS #143: Oncology: Medical and Radiation - Pain Intensity Quantified	Refinement to ensure the removal of Hormonal Therapy from the Denominator criteria.	Practices should see a slight shift in the Numerator and/or Denominator.
MIPS #144: Oncology: Medical and Radiation - Plan of Care for Pain	Refinement to ensure the removal of Hormonal Therapy from the Denominator criteria.	Practices should see a slight shift in the Numerator and/or Denominator.

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

NOTE: Table continues on the next page.

Measure	Description
MIPS Quality Measures Dashboard	
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#130	Current Medications Documentation
#134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Tobacco Screening and Cessation
#236	Controlling High Blood Pressure
#238	Use of High-Risk Medications in Older Adults
#374	Closing the Referral Loop
#450	Trastuzumab Received by Patients with AJCC Stage I (T1c), II and III and HER2+ Breast Cancer Receiving Adj Chemo
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#453	Percentage of Patients who Died from Cancer

Measure	Description
	Receiving Systemic Cancer-Directed Therapy in the Last 147 Days of Life (Inverse Measure)
#457	Patients Admitted to Hospice for < 3 Days
#462	Bone Density Evaluation of Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#8	Mutation Testing for Lung Cancer
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center